Slide 1: Investor Presentation ASX cover announcement
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 28 July 2026 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentation
Slide 2: Q4 FY26 Results
For personal use only Impedimed Limited Q4 FY26 Results 28 July 2026 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Agenda
Agenda For personal use only 1 Business Overview 2 Financial Performance 3 Q1 FY27 Outlook Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 3
Slide 5: Business Overview
For personal use only Business Overview Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 4
Slide 6: The SOZO Digital Health Platform Value Proposition
The SOZO® Digital Health Platform Value Proposition Strong foundation • Best-in-class, FDA-cleared, TGA-cleared, and CE-Marked cloud-based digital health platform delivering body For personal use only composition and fluid outputs, led by new Executive Leadership. Addressing fast growing healthcare
Slide 7: Q4 Key Highlights
Q4 Key Highlights Financial • Revenue $3.6m. For personal use only • TCV $5.4m. • Annual Recurring Revenue $14.4m ($14.6m in constant currency (vs. Q3 FY26)). • Quarterly operating cash outflow $4.9m. • Cash balance $15.3m, equating to 3.1 quarters of operating cash flow. • Capital raise completed r
Slide 8: Lymphoedema and Cancer Survivorship
Lymphoedema and Cancer Survivorship • 18M US cancer survivors, growing at 1M+/year 1, expanding multidisciplinary For personal use only clinician focus to supporting patient quality of life and reducing risk of cancer recurrence. • Up to 60% of cancer survivors report a fear of cancer recurrence 2,
Slide 9: Stakeholder Map
Stakeholder Map Breast Surgeon Clinical leader and influencer Survivorship Director VP Oncology Ops For personal use only Program leadership and care pathways Strategic priority and resource alignment Legal Champion Quality Leader Finance / Budget Value analysis, outcomes and clinical Financial eval
Slide 10: Heart Health
Heart Health • US outpatient heart failure monitoring market estimated at US$600 For personal use only million. • 6.7M1 HF patients in the US with ~1 million new patients diagnosed each year . • SOZO Pro is the only FDA-cleared BIS device for the assessment of fluid status in heart failure patients,
Slide 11: Medical Weight Management
Medical Weight Management • Strong momentum in Medical Weight Management, with a growing pipeline across key target segments and synergies For personal use only with Cancer Survivorship and Cardiology. • GLP-1 adoption is driving demand for body composition monitoring beyond weight alone. • SOZO pro
Slide 12: Financial Performance
For personal use only Financial Performance Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 11
Slide 13: Cash Flow
Cash Flow Summarized Cash Flow FY26 In thousands Q1 Q2 Q3 Q4 YTD For personal use only AUD Actual Actual Actual Actual Actual Receipts from customers 3,443 3,785 3,268 4,275 14,771 Research & development (62) (125) (48) (180) (415) • Q4 operating cash outflow of $4.9m, in-line with Product manufactu
Slide 14: TCV and ARR
TCV and ARR SOZO Core Business Total Contract Value1 SOZO Annual Recurring Revenue 2 For personal use only A$ millions A$ millions Vs. Q3 FY26: • Up $0.3m (2%) • Up $0.5m (4%) in CC3 • TCV of $5.4m flat vs. Q3 FY26 (up 2% in constant • In constant currency vs Q2 FY26, Q4 ARR of $15.5m, up $1.1m or 8
Slide 15: Global Installed Base and Patient Tests
Global Installed Base and Patient Tests Global Installed Base Patient Tests (000s) New measurement2 For personal use only ROW installed base Follow-up measurement U.S. installed base Units 16% 3-year CAGR1 • 40 SOZO units sold vs 36 Q3 FY26 • 87,000 patient tests in Q4 FY26 • U.S. unit sales 36 vers
Slide 16: Outlook for Q1 FY27
For personal use only Outlook for Q1 FY27 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2026 ImpediMed Limited. 15
Slide 17: Outlook for Q1 FY27
Outlook for Q1 FY27 ❑ US Cancer Survivorship o Drive Lymphedema+ strategy to land and expand within existing and new customers For personal use only o Lead with SOZO Pro in Lymphoedema & Survivorship o Refocus messaging to address multidisciplinary expansion o Leverage changes to sales team, reimbur
Slide 18: For personal use only
impedimed’ For personal use only 7